Tech Company Inital Public Offerings
Icosavax IPO
Icosavax was acquired by . Shares became public on 7/29/2021.
Transaction Overview
Company Name
Announced On
7/29/2021
Transaction Type
IPO
Amount
$150,000,000
Proceeds Purpose
Use of proceeds for the Icosavax IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2815 Eastlake Ave. E 300
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Undisclosed
Website
Email Address
Overview
We are committed to developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. We were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Simpson
Chief Medical Officer
Niranjan Kanesa-thasan
Chief Scientific Officer
Douglas Holtzman
VP - Operations
Charles Richardson
Browse more venture capital transactions:
Prev: 7/29/2021: MedRhythms venture capital transaction
Next: 7/29/2021: Contentful venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs